This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Amicus Therapeutics’s 8K filing here.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
See Also
- Five stocks we like better than Amicus Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
